Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma: Case Report

被引：2

作者：

d'Arienzo, Paolo D. ^{[1
]}

MacDonald, Alan R. ^{[1
]}

Patel, Virjen ^{[2
]}

Ma, Yuk T. ^{[3
]}

Pihlak, Rille ^{[4
]}

Starling, Naureen ^{[1
,5
]}

机构：

[1] Royal Marsden NHS Fdn Trust, GI Canc Unit, 203 Fulham Rd, London SW3 6JJ, England

[2] Royal Marsden NHS Fdn Trust, Clin Radiol Dept, London, England

[3] Univ Hosp Birmingham NHS Fdn Trust, Dept Oncol, Birmingham, England

[4] St Bartholomews Hosp, Dept Oncol, London, England

[5] Inst Canc Res, Div Clin Studies, London, England

来源：

ONCOTARGETS AND THERAPY | 2024年 / 17卷

关键词：

cholangiocarcinoma; FGFR inhibitor; targeted therapy; futibatinib; METASTATIC CHOLANGIOCARCINOMA; OPEN-LABEL; MULTICENTER;

D O I：

10.2147/OTT.S434449

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Multiple FGFR inhibitors have demonstrated significant activity in pretreated advanced FGFR2 fusion-positive intrahepatic cholangiocarcinoma. The irreversible pan-FGFR inhibitor futibatinib has the potential to overcome acquired resistance to ATPcompetitive FGFR inhibitors in a subset of patients. We present a case of prolonged clinical benefit using FGFR inhibitors sequentially, initially an ATP-competitive inhibitor followed by futibatinib upon progression, for a total of 36 months of FGFR-targeting therapy. This case supports sequential FGFR-targeting therapies for FGFR2 fusion-positive cholangiocarcinoma, with futibatinib acting as rescue therapy after failure of ATP-competitive inhibitors.

引用

页码：489 / 496

页数：8

共 27 条

[1] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].

Abou-Alfa, Ghassan K. ;

Sahai, Vaibhav ;

Hollebecque, Antoine ;

Vaccaro, Gina ;

Melisi, Davide ;

Al-Rajabi, Raed ;

Paulson, Andrew S. ;

Borad, Mitesh J. ;

Gallinson, David ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Dotan, Efrat ;

Catenacci, Daniel, V ;

Van Cutsem, Eric ;

Ji, Tao ;

Lihou, Christine F. ;

Zhen, Huiling ;

Feliz, Luis ;

Vogel, Arndt .

LANCET ONCOLOGY, 2020, 21 (05) :671-684

[2] Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression [J].

Aldea, Mihaela ;

Hendriks, Lizza ;

Mezquita, Laura ;

Jovelet, Cecile ;

Planchard, David ;

Auclin, Edouard ;

Remon, Jordi ;

Howarth, Karen ;

Benitez, Jose Carlos ;

Gazzah, Anas ;

Lavaud, Pernelle ;

Naltet, Charles ;

Lacroix, Ludovic ;

de Kievit, Frank ;

Morris, Clive ;

Green, Emma ;

Ngo-Camus, Maud ;

Rouleau, Etienne ;

Massard, Christophe ;

Caramella, Caroline ;

Friboulet, Luc ;

Besse, Benjamin .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) :383-391

[3]

[Anonymous], FoundationOne CDX Technical Information

[4] Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01 [J].

Busset, M. Droz Dit ;

Shaib, W. L. ;

Mody, K. ;

Personeni, N. ;

Damjanov, N. ;

Harris, W. P. ;

Bergamo, F. ;

Brandi, G. ;

Masi, G. ;

Halfdanarson, T. R. ;

Tam, V. ;

Goff, L. W. ;

Knox, J. ;

Hollebecque, A. ;

Macarulla Mercade, T. ;

Cantero, F. ;

Saulay, M. ;

Braun, S. ;

Javle, M. ;

Borad, M. .

ANNALS OF ONCOLOGY, 2021, 32 :S376-S376

[5]

clinicaltrials, A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations-ClinicalTrials.gov

[6]

Goyal L, 2021, First Results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors

[7] Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma [J].

Goyal, Lipika ;

Meric-Bernstam, Funda ;

Hollebecque, Antoine ;

Valle, Juan W. ;

Morizane, Chigusa ;

Karasic, Thomas B. ;

Abrams, Thomas A. ;

Furuse, Junji ;

Kelley, Robin K. ;

Cassier, Philippe A. ;

Kluempen, Heinz-Josef ;

Chang, Heung-Moon ;

Chen, Li-Tzong ;

Tabernero, Josep ;

Oh, Do-Youn ;

Mahipal, Amit ;

Moehler, Markus ;

Mitchell, Edith P. ;

Komatsu, Yoshito ;

Masuda, Kunihiro ;

Ahn, Daniel ;

Epstein, Robert S. ;

Halim, Abdel-Baset ;

Fu, Yao ;

Salimi, Tehseen ;

Wacheck, Volker ;

He, Yaohua ;

Liu, Mei ;

Benhadji, Karim A. ;

Bridgewater, John A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (03) :228-239

[8] Targeting FGFR inhibition in cholangiocarcinoma [J].

Goyal, Lipika ;

Kongpetch, Sarinya ;

Crolley, Valerie E. ;

Bridgewater, John .

CANCER TREATMENT REVIEWS, 2021, 95

[9] TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma [J].

Goyal, Lipika ;

Shi, Lei ;

Liu, Leah Y. ;

de la Cruz, Ferran Fece ;

Lennerz, Jochen K. ;

Raghavan, Srivatsan ;

Leschiner, Ignaty ;

Elagina, Liudmila ;

Siravegna, Giulia ;

Ng, Raymond W. S. ;

Phuong Vu ;

Patra, Krushna C. ;

Saha, Supriya K. ;

Uppot, Raul N. ;

Arellano, Ron ;

Reyes, Stephanie ;

Sagara, Takeshi ;

Otsuki, Sachie ;

Nadres, Brandon ;

Shahzade, Heather A. ;

DeyGuha, Ipsita ;

Fetter, Isobel J. ;

Baiev, Islam ;

Van Seventer, Emily E. ;

Murphy, Janet E. ;

Ferrone, Cristina R. ;

Tanabe, Kenneth K. ;

Deshpande, Vikram ;

Harding, James J. ;

Yaeger, Rona ;

Kelley, Robin K. ;

Bardelli, Alberto ;

Iafrate, A. John ;

Hahn, William C. ;

Benes, Cyril H. ;

Ting, David T. ;

Hirai, Hiroshi ;

Getz, Gad ;

Juric, Dejan ;

Zhu, Andrew X. ;

Corcoran, Ryan B. ;

Bardeesy, Nabeel .

CANCER DISCOVERY, 2019, 9 (08) :1064-1079

[10] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial [J].

Hollebecque, A. ;

Borad, M. ;

Goyal, L. ;

Schram, A. ;

Park, J. O. ;

Cassier, P. A. ;

Kamath, S. D. ;

Meng, D. T. Wai ;

Dotan, E. ;

Kim, R. ;

Sahai, V. ;

Oh, D-Y. ;

Liao, C-Y. ;

Millward, M. ;

Perez, D. Roda ;

Ferte, C. ;

Blakesley, R. ;

Wolf, B. ;

Subbiah, V. ;

Kelley, R. K. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S1381-S1381

← 1 2 3 →